Navigation Links
A High-Density Lipoprotein Raising Drug That Has a Lower Discontinuation Rate Than That of Extended Release Niaspan Would Earn a 20 Percent Patient Share in the Dyslipidemia Drug Market
Date:7/29/2008

Crestor Will Remain the Clinical Gold Standard Drug Through 2016, According

to a New Report from Decision Resources

WALTHAM, Mass., July 29 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug that raises high-density lipoprotein cholesterol and has a lower discontinuation rate than that of Abbott's Niaspan ER (extended release) would earn a 20 percent patient share in the treatment of dyslipidemia, according to surveyed endocrinologists.

The new report entitled Dyslipidemia: Blockbuster Potential for Agents that Target HDL finds that although lowering low-density lipoprotein cholesterol levels is at the forefront of treating dyslipidemia, researchers are now aware that increasing high-density lipoprotein cholesterol levels may also help reduce cardiovascular risk.

The report also finds that surveyed endocrinologists do not expect any therapy under development to displace AstraZeneca's Crestor as the Decision Resources' proprietary clinical gold standard for dyslipidemia through 2016. Although some therapies in development hold promise, most have efficacy, safety and tolerability, and/or delivery features that merit inferior scores compared with Crestor.

"For the majority of end points, endocrinologists we surveyed perceive the statin class to be very similar," said Graeme Green, Ph.D., analyst at Decision Resources. "However Crestor positively differentiates itself in its greater ability to improve low- and high-density lipoprotein cholesterol levels."

About the Report

Dyslipidemia: Blockbuster Potential for Agents that Target HDL is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CVS/pharmacy Raises Record-breaking $4.4 Million for ALS Research Through Annual ALS Fundraising Campaign
2. Cost of raising a child with special needs: Where does your state rank?
3. Camp Bow Wow(R) Launches Fundraising Effort to Help Cure Cancer in Dogs, via Morris Animal Foundations Canine Cancer Campaign - Dogs Get Bandanas; Camp Bow Wow in Indianapolis is Participating
4. Camp Bow Wow(R) Launches Fundraising Effort to Help Cure Cancer in Dogs, via Morris Animal Foundations Canine Cancer Campaign - Dogs Get Bandanas; Camp Bow Wow in Cincinnati is Participating
5. Camp Bow Wow(R) Launches Fundraising Effort to Help Cure Cancer in Dogs, via Morris Animal Foundations Canine Cancer Campaign - Dogs Get Bandanas; Camp Bow Wow Locations in Texas Participating
6. Camp Bow Wow(R) Launches Fundraising Effort to Help Cure Cancer in Dogs, via Morris Animal Foundations Canine Cancer Campaign - Dogs Get Bandanas; Camp Bow Wow Locations in New Jersey Participating
7. Camp Bow Wow(R) Launches Fundraising Effort to Help Cure Cancer in Dogs, via Morris Animal Foundations Canine Cancer Campaign - Dogs Get Bandanas; Camp Bow Wow Locations in Minnesota Participating
8. Camp Bow Wow(R) Launches Fundraising Effort to Help Cure Cancer in Dogs, via Morris Animal Foundations Canine Cancer Campaign - Dogs Get Bandanas; Camp Bow Wow Locations in Michigan Participating
9. Camp Bow Wow(R) Launches Fundraising Effort to Help Cure Cancer in Dogs, via Morris Animal Foundations Canine Cancer Campaign - Dogs Get Bandanas; Camp Bow Wow Locations in Colorado Participating
10. Camp Bow Wow(R) Launches Fundraising Effort to Help Cure Cancer in Dogs, via Morris Animal Foundations Canine Cancer Campaign - Dogs Get Bandanas; Camp Bow Wow Locations in California Participating
11. Camp Bow Wow(R) Launches Fundraising Effort to Help Cure Cancer in Dogs, via Morris Animal Foundations Canine Cancer Campaign - Dogs Get Bandanas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... ... Lori G. Cohen and Sara K. Thompson , shareholders in global law ... 21st Drug & Medical Device Litigation Conference , taking place in New York Dec. ... chairs the firm’s Pharmaceutical, Medical Device & Health Care Litigation Practice and the Trial ...
(Date:12/2/2016)... ... , ... Advanced Inc., a leading provider of travel therapy and travel nursing ... as Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. Jason previously served as ... operational leadership experience to Advanced Inc. He began his career in finance at Ernst ...
(Date:12/2/2016)... ... ... With the number of pain management programs available for people suffering with constant ... works for them. When an inventor from Suisun City, Calif., was unsuccessful in finding ... it with others. , He developed a prototype for PRO GO MASSAGE to relieve ...
(Date:12/2/2016)... ... December 02, 2016 , ... CloudLIMS.com, a ... SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, research and testing laboratories ... and disposal. The new version is a faster and a more efficient product, ...
(Date:12/2/2016)... ... 02, 2016 , ... Yisrayl Hawkins, at The House of Yahweh in Abilene, ... into Bible Prophecy. Yisrayl says this generation, known as the Last Generation, started in ... the details line up exactly with Bible Prophecy – a protected way for those ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , December 2, 2016 On ... Committee honored excellence in research, development and innovation in ... gala dinner was held in the presence of Sergey ... Russian Federation , Natalia Sanina, First ... Mikhail Murashko , Head of Roszdravnadzor, National Service of ...
(Date:12/2/2016)... CVS Health Corporation (NYSE: CVS ... City on Thursday, December 15, 2016, beginning at 8:00 a.m. (ET). Senior ... an in-depth review of the company,s strategies to drive ... also discuss 2017 earnings guidance during the event. ... will be broadcast simultaneously on the Investor Relations portion ...
(Date:12/2/2016)... -- On Thursday, the NASDAQ Composite and the ... Dow Jones Industrial Average managed to stay in green. Losses ... prompted Stock-callers this morning to look at the performances of ... ), Smith & Nephew PLC (NYSE: SNN ), ... Therapeutics Inc. (NASDAQ: KOOL ). You can access ...
Breaking Medicine Technology: